XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
EQ Equillium
- 0.9397
- -0.0003-0.03%
Close Feb 14 16:00 ET
- 0.8899
- -0.0498-5.30%
Post 19:29 ET
33.29MMarket Cap-7.83P/E (TTM)
0.9796High0.8563Low183.52KVolume0.9200Open0.9400Pre Close166.00KTurnover1.02%Turnover RatioLossP/E (Static)35.43MShares3.250052wk High1.44P/B16.90MFloat Cap0.493052wk Low--Dividend TTM17.99MShs Float27.0500Historical High--Div YieldTTM13.12%Amplitude0.4500Historical Low0.9040Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Equillium Stock Forum
Phase 2 Clinical Success: New UC Treatment Achieves 23.3% Remission Rate, Rivaling Industry Standard
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Thursday, 6th February at 8:00 am
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Itolizuma...
Equillium Announces Positive Data From Phase 2 Study Evaluating Itolizumab in Patients With Moderate to Severe Ulcerative Colitis
is this stock still even alive
$Equillium (EQ.US)$
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads...
No comment yet